SynthesisBMJ (Clinical research ed.)2019

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.

Giovanni Musso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.